Document is current
Any future updates will be listed below
-
Authors
Briest, Franziska https://orcid.org/0000-0001-5969-9467
Noerenberg, Daniel
Hennch, Cornelius https://orcid.org/0000-0003-4104-5531
Yoshida, Kenichi https://orcid.org/0000-0003-4612-2778
Hablesreiter, Raphael https://orcid.org/0000-0002-4586-932X
Nimo, Jose
Sasca, Daniel https://orcid.org/0000-0003-0330-7959
Kirchner, Marieluise
Mansouri, Larry
Inoue, Yoshikage
Wiegand, Laura https://orcid.org/0000-0002-9917-7396
Staiger, Annette M. https://orcid.org/0000-0002-5896-3200
Casadei, Beatrice
Korkolopoulou, Penelope
Weiner, January https://orcid.org/0000-0003-1438-7819
Lopez-Guillermo, Armando
Warth, Arne
Schneider, Tamás
Nagy, Ákos https://orcid.org/0000-0001-6118-0365
Klapper, Wolfram
Hummel, Michael https://orcid.org/0000-0001-6717-605X
Kanellis, George
Anagnostopoulos, Ioannis https://orcid.org/0000-0002-5043-6043
Mertins, Philipp
Bullinger, Lars
Rosenquist, Richard https://orcid.org/0000-0002-0211-8788
Vassilakopoulos, Theodoros P.
Ott, German
Ogawa, Seishi https://orcid.org/0000-0002-7778-5374
Damm, Frederik https://orcid.org/0000-0001-5553-1173
-
Funding
Funding for this research was provided by:
Deutsche Krebshilfe
- License Information
-
More Information
Article History
Received: 18 January 2023
Revised: 15 August 2023
Accepted: 22 August 2023
First Online: 30 August 2023
Competing interests
: FB received honoraria from Ipsen Pharma and funding from Novartis, both unrelated to the project. DN received honoraria from Incyte Biosciences and Gilead. RR received honoraria from AbbVie, AstraZeneca, Janssen, Illumina and Roche. LB has received honoraria from AbbVie, Amgen, Astellas, BristolMyers Squibb, Celgene, Daiichi Sankyo, Gilead, Hexal, Janssen, Jazz Pharmaceuticals, Menarini, Novartis, Pfizer, Roche, Sanofi, and Seattle Genetics, and has received research support from Bayer and Jazz Pharmaceuticals. FD reports personal fees from AbbVie, AstraZeneca, Gilead, Incyte, Novartis, and Roche outside the submitted work. The other authors declare that they have no competing financial interests.
